These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35521334)
1. Retracted Article: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells. Chen G; Ye L; Han Y; Han P RSC Adv; 2019 Jul; 9(37):21139-21146. PubMed ID: 35521334 [TBL] [Abstract][Full Text] [Related]
2. Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells. Fisher L RSC Adv; 2021 Jan; 11(9):5265. PubMed ID: 35427004 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876 [TBL] [Abstract][Full Text] [Related]
5. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161 [TBL] [Abstract][Full Text] [Related]
6. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523 [TBL] [Abstract][Full Text] [Related]
7. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib. Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779 [TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
13. Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with Yoshida K; Kanda S; Shiraishi H; Goto K; Itahashi K; Goto Y; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y J Thorac Dis; 2019 Apr; 11(4):1347-1354. PubMed ID: 31179076 [TBL] [Abstract][Full Text] [Related]
14. Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640 [TBL] [Abstract][Full Text] [Related]
15. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003 [TBL] [Abstract][Full Text] [Related]
16. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446 [TBL] [Abstract][Full Text] [Related]
17. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
18. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288 [TBL] [Abstract][Full Text] [Related]
19. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]
20. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5. Li Q; Wang Y; He J J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]